Omeprazole Delayed-Release Capsules
 |
Marketed by:
Teva Pharmaceuticals
(North Wales, PA)
Compared to:
Prilosec (AstraZeneca)
Indication:
Teva Pharmaceuticals
announced the launch of
Omeprazole Delayed-Release Capsules, 40 mg. It is
AB-rated and bioequivalent to AstraZeneca’s Prilosec
Delayed-Release Capsules. The new 40-mg strength is available in 100- and 1000-count bottles.
The product is a proton pump inhibitor indicated
for the treatment of duodenal and
gastric ulcers in adults, gastroesophageal
reflux disease in pediatric patients and
adults, maintenance and healing of erosive
esophagitis in pediatric patients and adults,
and treatment of pathologic hypersecretory
conditions in adults.
Dosage Form:
Capsules: 10, 20, and 40 mg
For More Information:
www.tevausa.com
888-TEVA-USA (888-838-2872)
Lamotrigine Tablets and Lamictal CD Tablets
 |
Marketed by:
Mylan Pharmaceuticals Inc (Pittsburgh, PA)
Compared to:
Lamictal and Lamictal CD (GlaxoSmithKline)
Indication:
Mylan Pharmaceuticals Inc and Genpharm
ULC, both subsidiaries of Mylan Inc, received
FDA approval for their abbreviated new drug
applications (ANDAs) for Lamotrigine Tablets. Genpharm
also received FDA approval for its ANDA for Lamotrigine Tablets Chewable Dispersible (CD). Lamotrigine
Tablets were approved for 25-, 100-, 150-, and 200-mg
strengths. Lamotrigine CD gained approval for 5- and
25-mg strengths. These products are indicated for the
treatment of epilepsy and for maintenance treatment of
bipolar I disorder.
Dosage Form:
Tablets: 25, 100, 150, and 200 mg
Chewable Dispersible: 5 and 25 mg
For More Information:
www.mylan.com
Sumatriptan Succinate Tablets
 |
Marketed by:
Ranbaxy Pharmaceuticals Inc (Jacksonville, FL)
Compared to:
Imitrex Tablets (GlaxoSmithKline)
Indication:
Ranbaxy Pharmaceuticals Inc received final FDA
approval for its abbreviated new drug application for
sumatriptan succinate tablets, 100 mg. Sumatriptan
succinate tablets are indicated for the acute treatment
of migraine attacks with or without aura in adults.
They are not intended for the prophylactic therapy of
migraine or for use in the management of hemiplegic
or basilar migraine. Safety and effectiveness of sumatriptan
succinate tablets have not been established for
cluster headache.
Dosage Form:
Tablets: 100 mg
For More Information:
1-888-RANBAXY
Divalproex Sodium Capsules
 |
Marketed by:
Zydus Pharmaceuticals,
Inc (Princeton, NJ)
Compared to:
Depakote (Abbott
Laboratories)
Indication:
Zydus announced FDA approval for its abbreviated new
drug application for Divalproex Sodium Capsules. The
product is the generic version of Abbott Laboratories’
Depakote. Divalproex Sodium Capsules are indicated as
a monotherapy and adjunctive therapy of complex partial
seizures and simple and complex absence seizures.
The product also is indicated as an adjunctive therapy
in patients with multiple seizure types that include
absence seizures.
Dosage Form:
Capsules: 125 mg
For More Information:
www.zydususa.com